Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zhejiang Cuize Biopharmaceutical
Hangzhou, Zhejiang, Chinacuizebio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Zhejiang Cuize Biopharmaceutical is a clinical-stage biopharmaceutical company based in Hangzhou, China, dedicated to the development of innovative small molecule drugs for autoimmune diseases and oncology. The company's research focuses on highly selective kinase inhibitors, with a lead program, CZ-001, targeting Janus kinase 1 (JAK1). CZ-001 is currently in Phase 2 clinical trials for atopic dermatitis and is being explored for other inflammatory conditions. Cuize Biopharmaceutical leverages its internal medicinal chemistry expertise to create a pipeline of differentiated therapies aimed at addressing significant unmet medical needs in the global market.
- Therapeutic areas
- OncologyDermatologyImmunology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Zhejiang Cuize Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang Cuize Biopharmaceutical.